Stockscreener 앱 받기
101.01
0.11%
0.11
시장 영업 전:
100.70
-0.31
-0.31%
전일 마감가:
$100.90
열려 있는:
$100.92
하루 거래량:
14.48M
Relative Volume:
3.38
시가총액:
$19.14B
수익:
$2.83B
순이익/손실:
$-1.02B
주가수익비율:
-18.33
EPS:
-5.51
순현금흐름:
$194.14M
1주 성능:
+50.42%
1개월 성능:
+56.27%
6개월 성능:
+77.37%
1년 성능:
+90.91%
1일 변동 폭
$100.92
$101.26
1주일 범위
$66.00
$101.87
52주 변동 폭
$38.81
$101.87
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
EXAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
101.01 | 19.15B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
586.07 | 220.72B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.98 | 160.62B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
752.14 | 57.96B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
153.60 | 42.88B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
228.18 | 38.30B | 15.90B | 1.28B | 2.21B | 7.2842 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Halper Sadeh LLC Encourages GDOT, BLFY, EXAS Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Exact Sciences stock rating downgraded to Hold by TD Cowen following Abbott deal - Investing.com
Canaccord Genuity downgrades Exact Sciences stock to Hold after Abbott deal - Investing.com
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium - Markets Financial Content
UBS raises Exact Sciences stock price target to $105 on Abbott deal - Investing.com
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare
Exact Sciences (EXAS) Downgraded to Hold by Benchmark Analyst | EXAS Stock News - GuruFocus
Here are Monday’s Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - MSN
Exact Sciences (EXAS) Receives Downgrade from Jefferies Amidst P - GuruFocus
Here are Monday's Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More - 24/7 Wall St.
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Jefferies downgrades Exact Sciences stock to Hold after Abbott acquisition - Investing.com
Jim Cramer on Abbott: “I Think It’s a Terrific Time to Do Some Buying” - Yahoo! Finance Canada
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - MSN
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks - Finviz
Abbott’s (ABT) Exact Sciences Deal is “Very, Very Important,” Says Jim Cramer - Insider Monkey
Halper Sadeh LLC Encourages EXAS, NVRI, MRUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences CorporationEXAS - Barchart.com
Analysts Are Bullish on These Healthcare Stocks: Nano-X Imaging (NNOX), Exact Sciences (EXAS) - The Globe and Mail
Exact Sciences Corp Executives Engage in Stock Transactions - TradingView
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
VP Orville Sells 5,000 ($375K) Of Exact Sciences Corp [EXAS] - TradingView
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits - MSN
EXASExact Sciences Corp Stock Price and Quote - Finviz
Exact Sciences likely needs to see over $100/share in takeoveranalyst - MSN
Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle - Benzinga
Exact Sciences (EXAS): Wells Fargo Downgrades Rating, Raises Pri - GuruFocus
Abbott Laboratories to acquire Exact Sciences for $23B in largest-ever diagnostics deal - The Business Journals
Exact Sciences (EXAS) Receives Downgrade from William Blair | EX - GuruFocus
Abbott Labs stock to acquire Exact Sciences for $21 billion - Investing.com
Abbott Labs stock to acquire Exact Sciences for $21 billion By Investing.com - Investing.com UK
Exact Sciences (EXAS) Downgraded to Neutral by Guggenheim | EXAS Stock News - GuruFocus
EXAS: Barclays Downgrades Exact Sciences, Raises Price Target to $105 | EXAS Stock News - GuruFocus
Here Are Friday’s Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - Yahoo Finance
Abbott Labs stock gains as UBS reiterates Buy rating on Exact Sciences deal - Investing.com
Here Are Friday's Top Wall Street Analysts Research Calls: Advanced Micro Devices, Block, Broadcom, Exact Sciences, Hologic, Palo Alto Networks and More - 24/7 Wall St.
Exact Sciences joins Abbott, shares soar 18% on acquisition and growth prospects - Mugglehead Magazine
Abbott Eyes Exact Sciences: Market Stir - StocksToTrade
Halper Sadeh LLC Encourages CIVI, JAMF, EXAS Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Exact Sciences, Leader in Cancer Screening and Genomics Testing, to Join Abbott Laboratories in 2026 - Morningstar
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday - MSN
Abbott Laboratories $23B purchase of Cologuard maker Exact Sciences could have Arizona implications - The Business Journals
Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion - MSN
Why Exact Sciences Stock Surged Today - Finviz
Abbott Laboratories to acquire Exact Sciences in deal worth up to $23B - The Business Journals
Why Exact Sciences Rallied Over 50% This Week - Nasdaq
Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here? - Yahoo Finance
Abbott Laboratories, Exact Sciences make $23B deal with Bay Area implicationsSan Francisco Business Times - The Business Journals
EXAS Shares Soar Amid Acquisition Rumors - timothysykes.com
Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More - Investopedia
Exact Sciences (EXAS) Soars Over 17% in Stock Market Surge - GuruFocus
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.35%
1.41%
자본화:
|
볼륨(24시간):